RVT 802

Drug Profile

RVT 802

Alternative Names: RVT-802

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University
  • Developer Duke University; Enzyvant Sciences
  • Class
  • Mechanism of Action Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Di George syndrome
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Di George syndrome

Most Recent Events

  • 01 Jul 2018 Roivant Sciences files rolling BLA for Di-George syndrome in USA
  • 28 Jun 2018 Preregistration for Di-George syndrome in USA (Parenteral) (Enzyvant pipeline, June 2018)
  • 05 Sep 2017 RVT 802 receives Rare Paediatric Disease designation from US FDA for Di-George syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top